Human Alzheimer's brain contains PrP C -binding Aβ species Abo has been obtained from multiple sources, including synthetic peptide, transgenic mouse brain, transfected cell lines and the brains of individuals with Alzheimer's disease [1] [2] [3] [4] . To advance pathophysiological understanding, it is of greatest importance to examine the action of Abo derived from the brains of individuals with Alzheimer's disease. Notably, Abo derived from the brains of individuals with Alzheimer's disease requires PrP C to suppress LTP 10, 16 . Thus, we assessed PrP C -interacting Abo from human Alzheimer's disease tissue for Fyn activation (Fig. 3) .
We developed a sensitive assay for the detection of Ab species that interact with PrP C (Fig. 3a) . The 23-111 Ab-interacting domain of PrP C was purified from recombinant E. coli and immobilized in microtiter plates. Specimens containing Abo were added, and bound Ab was detected using antibody to Ab. Detection of PrP C -bound Abo was robust with N terminus-directed Ab antibodies (polyclonal 2454 and monoclonal 82E1; Supplementary Fig. 5a ) or with an antibody to Ab that detects only oligomeric species (NU-4, data not shown), PSD relative to initial homogenate. Fyn kinase was enriched threefold in PSDs. We also observed substantial colocalization of PSD-95 with PrP C immunoreactivity in hippocampal cultures (Fig. 1c) . Thus, PrP C is present in the PSD, where it can mediate the effects of Abo.
Aβo binding to PrP C generates Fyn kinase activation
The nonreceptor tyrosine kinase Fyn is a possible mediator of signal transduction from the Abo-PrP C complex. It is possible to monitor the activation of Src family kinases (SFKs) by measuring the expression of phosphospecific epitopes. We examined cultures for SFK activation after 15-min exposure to Ab species ( Fig. 2 and Supplementary  Figs. 1-4) . Wild-type cortical neurons at 21 d in vitro (DIV) showed increased levels of pY416-Fyn (SFK) in response to Abo (Fig. 2a,c) . The phospho-specific antibody used in these immunoblots detects pY416 in several SFKs, but kinase-specific immunoprecipitation revealed that PrP C -dependent activation was Fyn specific (Supplementary Fig. 1a ). Fyn activation was oligomer specific; no activation was detected after exposure to monomeric Ab ( Fig. 2c and Supplementary Fig. 1b ) or fibrillary Ab (Supplementary Fig. 1c,d) .
We asked whether PrP C is required for the Abo-induced Fyn activation. Previously, we found that Abo binding to PrP C is blocked by antibody to PrP C (6D11) 5 . This antibody also prevented Fyn activation by Abo (Fig. 2a,c) . Notably, in Prnp -/-cultures, activation of Fyn by Abo was eliminated (Fig. 2b,c) . Although Abo failed to activate Fyn in Prnp -/-neurons, Reelin-induced Fyn activation was preserved (Fig.  2d,e) . Thus, although PrP C accounts for ~50% of Abo binding sites 5, 33 , it accounts fully for Fyn signaling.
We also verified that Abo induced PrP C -dependent Fyn activation in cell lines. Stably transfected CV-1 cells expressing PrP C (SCA-7), Fyn or both were generated (Supplementary Fig. 2a ). PrP C protein per mg of total protein in parental CV-1 cells was less than 5% of the concentration in brain, and the level in PrP C expressors was 50-100% of brain (data not shown). Abo increased the amount of pY416-SFK twofold exclusively in cells expressing both PrP C and Fyn ( Supplementary Fig.  2a,b) . In N2A neuroblastoma, similar PrP C -dependent, Abo-induced Fyn activation was observed in detergent-insoluble subcellular fractions ( Supplementary Fig. 2c,d ), although activation was not detected in HEK293T cells. We conclude that Abo-PrP C complexes activate Fyn in many cell types.
A marker of Abo-induced PrP C -Fyn signaling is physical proximity of the proteins. In untreated CV-1 or HEK cells, a proportion of Fyn coimmunoprecipitated with PrP C (Supplementary Fig. 3a,b) . Association was increased by Abo treatment. An Abo-induced complex was also Having detected PrP C -interacting Ab in the brains of individuals with Alzheimer's disease, we sought to determine whether these assemblies activate neuronal Fyn (Fig. 3c-e) . Extracts from Alzheimer's disease brains (6 mg protein per ml) stimulated Fyn activation in mouse cortical cultures, but extracts from control brains did not (P < 0.05; Fig.  3c,d ). To assess whether this actvation was a result of PrP-interacting species, we pre-absorbed human TBS brain extracts with PrP C -Fc affinity resin. PrP C -Fc resin, but not Fc control resin, prevented Fyn activation (Fig. 3c,e) . The Ab dependence of Fyn activation was assessed with antibody to Ab (82E1) and abrogation was observed (Fig. 3c,e) . As for synthetic Abo stimulation of Fyn, the signaling induced by Alzheimer's disease TBS extracts was absent in Prnp -/-cells and in cells pretreated with the 6D11 antibody to PrP C (Fig. 3c,e) . Moreover, the level of PrP Cinteracting Ab species in human brain extracts correlated with the level of Fyn activation (Fig. 3f) . Thus, TBS-soluble Ab derived from the brains of individuals with Alzheimer's disease stimulates neuronal Fyn via PrP C .
NMDAR subunits phosphorylated by Aβ-PrP C -Fyn signaling NMDARs are important for synaptic plasticity and Alzheimer's disease. Intracellular segments of NR2A and NR2B subunits contain tyrosine residues phosphorylated by SFKs 36 . Thus, Abo-PrP C -mediated Fyn activation may be directed towards NMDAR. We examined total NR2B and pY1472 NR2B levels in neuroblastoma cells expressing Fyn, PrP C or NR2B after exposure to Abo (Supplementary Fig. 6a ). pY1472 NR2B expression was selectively increased by Abo treatment but not with C terminus-directed antibodies, including AB5306 (Supplementary Fig. 5a ). This may be a result of the inaccessibility of the Ab C terminus in oligomeric assemblies under native conditions. Using purified Abo, the assay has a linear range from 20-14,000 pg (Fig.  3a) . The specificity for oligomeric Ab over monomeric Aß or fibrillary Ab exceeded 30-fold (Fig. 3a) .
We assessed PrP C -interacting Ab species in Tris-buffered saline (TBS) homogenates of brain cleared by ultracentrifugation. PrP C -interacting Ab was detected in transgenic APP/PSen mouse brain, but not in wild-type brain (using synthetic Abo as a standard: transgenic, 394 ± 72 ng of Ab per g of brain, n = 9 brains; wild type, <15, n = 7 brains; mean ± s.e.m., P < 0.001, ANOVA, F = 28.48, degrees of freedom = 1). We measured PrP C -interacting Abo in TBS-soluble cortical extracts from a cohort of autopsy-confirmed cases of Alzheimer's disease versus controls. The average level in control brains was below the detection limit, whereas samples from cases of Alzheimer's disease contained 20.8+2.6 ng of Ab per g of brain (mean ± s.e.m., P < 0.001; Fig. 3b ). This value suggests that a substantial proportion of Ab in TBS-soluble extracts from Alzheimer's disease brains interacts with PrP C . ELISA measurement revealed that ~50% of Ab42 immunoreactivity in TBS-soluble Alzheimer's disease extracts absorbed to PrP-coated wells (Supplementary Fig. 5b ). Urea elution recovered ELISA-detectable Ab42 selectively from PrP(23-111) wells exposed to Alzheimer's disease extracts (Supplementary Fig. 5c ). Urea allowed >100% recovery of initial Aß42 ELISA signal ( Supplementary  Fig. 5b,c) , likely as a result of denaturation of secondary structure in Ab or associated proteins, which would otherwise limit detection. Fig. 7a,c) .
During the first 15 min of Abo treatment, NR2B phosphorylation was enhanced, but after 1-3 h, phosphorylation was suppressed (Fig.  4c,d ). Abo is known to increase the level of STEP tyrosine phosphatase 23, 37 . Given that STEP and Fyn counteract one another, we compared the time course of these events relative to NR2B phosphorylation ( Fig. 4c,d ). At the onset of Abo action, Fyn was activated and pY1472 NR2B expression was increased, with no change in STEP protein level. Later on, STEP increased while Fyn returned to baseline, with a net decrease in NR2B phosphorylation. Thus, a biphasic effect of Abo on NR2B is triggered by PrP C engagement.
in Fyn-overexpressing cells. This increase was blocked by the 6D11 antibody to PrP C . Next, we studied endogenous proteins in cortical cultures exposed to Abo (Fig. 4a,b) . Over 20 min, Abo induced a dosedependent fivefold increase in pY1472 NR2B expression. This effect was specific for the oligomeric Ab, as fresh Ab had no effect (data not shown). Abo-induced NR2B phosphorylation was eliminated in Prnp -/- (Fig. 4a,b) and Fyn -/-cultures ( Supplementary Fig. 7b ) and by the 6D11 antibody to PrP C (Fig. 4a,b) . Thus, Abo-induced phosphorylation of Y1472 in NR2B is a PrP C -Fyn-mediated signaling event. Changing surface levels of NMDAR are expected to mediate alterations in NMDA-induced calcium levels. We used a calcium-sensitive fluorescent dye to monitor intracellular calcium in cortical neurons. NMDA produced increased fluorescence signal microscopically (Supplementary Movie 1) and in microtiter wells (Fig. 5g) . Pretreatment with Abo for 15 min generated significantly increased (P < 0.05) NMDA-induced signal, as predicted. By 60 min, when NR2B receptors were dephosphorylated and internalized, NMDA-induced calcium signals were suppressed (Fig. 5g) . In cortical neurons lacking PrP C , Abo did not alter NMDA responsiveness (Fig. 5g) . The Ab effect was oligomer specific, as neither Ab monomers nor Ab fibrils altered NMDA responses (Supplementary Fig. 8d ). Bath application of glutamate produced elevations of intracellular calcium that were mediated by NMDARs and by other channels. Pretreatment with Abo for 1 h suppressed glutamate responses in wild-type, but not in Prnp -/-or Fyn -/-, neurons ( Supplementary Fig. 8a-c) . Thus, Abo-induced, PrP Cmediated alterations in NMDAR create transient increases and then decreases in neuronal calcium.
We considered whether the transient increase in surface NR2B might lead to a brief period of excitotoxicity. We first examined N2A cells Surface NMDAR and calcium signaling induced by Ab-PrP C -Fyn Phosphorylation of NR2B at Y1472 is known to reduce AP-2-mediated endocytosis 38 . Using cell surface biotinylation, we examined the extent to which NR2B is accessible at the cell surface versus being sequestered intracellularly (Fig. 5a-d) . In concert with the pY1472 NR2B increase, we observed an increase in the amount of biotinylated NR2B shortly after Abo exposure (Fig. 5a,d) . There was no change in total NR2B expression. The increase was transient and was followed by a suppression of surface NR2B below baseline, matching the late decrease in pY1472 NR2B. Both the early and late surface NR2B response to Abo required PrP C and Fyn, as evidenced by the lack of response in Prnp -/-, Fyn -/-and 6D11-treated cultures (Fig. 5a-d) . The levels of PrP C were limiting, with a substantial reduction in short-term Abo-induced NR2B relocalization in Prnp +/-neurons (Supplementary Fig. 7d) . The biochemical changes can be imaged using an extracellularly GFP-tagged NR2B 39 . The ratio of surface to total NR2B protein was detected by assessing the immunostaining for GFP without permeablization and the intrinsic GFP fluorescence (Fig. 5e,f) . In wild-type neurons, Abo tripled this ratio at 15 min with a return to baseline by 60 min. There was no change in neurons that lacked PrP C . (Fig. 5h) . A requirement for PrP C in Abo-induced neuronal cell death matches recent reports 15, 20 . Genetic deletion of either Fyn or PrP C rescued neurons from Abo (Fig. 5h) . Heterozygosity for null alleles of Prnp or Fyn reduced LDH release (Supplementary Fig. 7e ).
For transheterozygous Prnp +/-and Fyn +/-neurons, there was no detectable Abo-induced LDH release during the first 90 min ( Supplementary  Fig. 7e ). The toxicity depended primarily on NMDAR, as LDH release was reduced by d(-)-2-amino-5-phosphonovaleric acid (AP5), and on NR2B-containing receptors, as ifenprodil suppressed LDH release (Fig. 5i) . Consistent with excitoxic, non-apoptotic cell toxicity, there was no increase the amount of in activated caspase 3 ( Supplementary  Fig. 9c,d) . Thus, Abo requires PrP C to induce Fyn activation and subsequent NR2B phosphorylation. This phosphorylation is associated with transient increase in NR2B at the cell surface, with consequent excitotoxicity.
Aβo destabilization of dendritic spines requires PrP C -Fyn
A hallmark of Alzheimer's disease is synaptic loss 40 . In vitro studies have described dendritic spine loss after acute Abo exposure 3, 21, 22 . We sought to determine whether PrP C and Fyn are involved with this loss.
with and without overexpression of Fyn and PrP C . Combined expression of Fyn and PrP C substantially increased the release of cellular lactate dehydrogenase (LDH) induced by a 90-min exposure to Abo (Supplementary Fig. 6b ). To examine the role of endogenous PrP C and Fyn in Abo neuronal toxicity, we used primary cortical cultures. Brief exposure to Abo reduced cell viability, and 10% of cellular LDH was released into the medium ( Fig. 5h and Supplementary Fig. 8e) . A decrease in 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) chemical reduction was not detectable, as it was in the range of variability of the assay (Supplementary Fig. 9a ). When Abo exposure was extended to 72 h, no further LDH release was observed ( Supplementary Fig. 9b ), indicating that this cell toxicity occurs largely during the initial 90 min of Abo exposure, when surface NR2B is increased. To determine whether the correlation of acute Abo cell toxicity with surface expression of NR2B and Ab-PrP-Fyn signaling is functional, we examined the effects of antibody and genetic blockade. Pretreatment with the 6D11 antibody to PrP C prevented the Abo-induced LDH Fig. 10 ).
Different Aβ oligomer species and mechanisms
Abo derived from synthetic peptide, cell culture, transgenic brains and the brains of individuals with Alzheimer's disease has been analyzed in various functional and biochemical assays. The Ab peptide can assume different oligomeric states, each distinct from monomer or fibrillary peptide. The resolution of oligomeric Ab forms is not defined biophysically, although molecular weight and/or valency clearly differ between preparations. Variable outcomes in functional experiments with different Abo preparations may be the results of uncharacterized variation between preparations 10 . We found that Abo from the brains of individuals with Alzheimer's disease interacts with PrP C , confirming the pathological relevance of the studies. Suppression of LTP by extracts from the brains of individuals with Alzheimer's disease has also been reported to require PrP C (refs. 10,16) . The ability of Abo species to interact with PrP(23-111) distinguishes a subset of peptide with deleterious actions on neurons and synapses. The level of PrP C -interacting Ab species in TBS-soluble extracts from the brains of individuals with Alzheimer's disease is within the range of values determined by previous studies [43] [44] [45] . Measurements of Ab after immunoprecipitation or immunoblot of TBS-soluble extracts from the brains of individuals with Alzheimer's disease have yielded values 43 very similar to those that we observed for PrP C -interacting species. This raises the possibility that a substantial fraction of Ab in the brains of individuals with Alzheimer's disease is capable of interacting with PrP(23-111). Further analysis of human samples for PrP C -interacting Ab species may provide a useful tool for following disease status and/ or treatment efficacy.
Postsynaptic action of Aβo-PrP C complexes Synapse loss is among the most prominent and consistent aspects of Alzheimer's disease 40 . Using immunohistochemical localization and subcellular fractionation, we found that PrP C was concentrated at synapses and enriched in PSD. These findings are consistent with several unbiased proteomic studies examining PrP C in PSD fractions 46, 47 , and PrP C is included in a 'consensus PSD' data set 34 . PSD localization is consistent with PrP C being involved in mediating the local effects of Abo on synaptic plasticity, dendritic spine retraction and synaptic loss. Indeed, our genetic analysis revealed that both PrP C and Fyn are required for dendritic spine loss. Previous studies have shown that chronic loss of synaptic markers in transgenic Alzheimer's disease mice requires PrP C (refs. 13,14) . However, another study found that Ab-induced loss of dendritic spines in culture is independent of PrP C (ref. 12). The PrP Cnegative result may reflect differences in the Ab preparation. In this regard, the observation that PrP C -Fc recognizes Alzheimer's diseasederived Ab species supports the idea that PrP C -dependent pathways are important for Alzheimer's disease.
Engagement of an Abo-PrP C -Fyn pathway increased NMDAR phosphorylation and altered receptor localization. The biphasic effect on surface NMDAR was coupled with short-term cell toxicity, followed by a loss of surface receptor. Both acute augmentation and chronic suppression of NMDA responses by Abo have been reported 18, 21, 48 . Future studies of GluR trafficking could delineate the sites of receptor relocalization in the neuron relative to synapses, as well as the timing of Abo-PrP C -Fyn induced changes in neurotransmission.
To provide a robust measure for fractional loss, we repeatedly imaged the same dendritic segments expressing membrane-tethered enhanced GFP (EGFP) over a 6-h period (Fig. 6a and Supplementary Movie 2) . Under control conditions, dendritic spines were stable, with less than 2% gains or losses. Abo treatment increased spine loss, without substantial alteration of spine gain. Over 5 h, 10-15% of spines were lost following Abo treatment, whereas adjacent spines were morphologically stable (Fig.  6) . The time course was gradual after an initial lag (Fig. 6b) . Although loss was increased fivefold following Abo treatment, the loss remained minor compared with the variability of spine density, emphasizing the need for time-lapse imaging.
To assess the roles of PrP C and Fyn in Abo-induced spine loss, we cultured neurons from embryos homozygous for null alleles (Fig.  6a,c) . Spine destabilization by Abo was eliminated in Prnp -/-and Fyn -/-neurons. Thus, Abo-induced spine loss requires both PrP C and Fyn. We also tested whether Abo-induced spine loss requires NMDAR. As seen in previous studies with Ab species derived from individuals with Alzheimer's disease 3 , the NMDA antagonist AP5 blocked dendritic spine loss by Abo (Fig. 6c) .
Pmp loss prevented seizures in Alzheimer's disease mice Epileptiform discharges have been observed in transgenic mouse models of Alzheimer's disease and seizures are more common in Alzheimer's disease 41 . We hypothesized that network instability may derive from Ab-PrP C -Fyn-induced alterations in synapses. We examined epileptiform discharges of >5 s in APPswe/PSen1∆E9 transgenic mice with or without PrP C expression at 9-10 months of age (Fig. 7a,b) . After implantation of intracranial electrodes, continuous video and electroencephalography (EEG) records were monitored for 72 h. Consistent with previous studies 42 , 40% of the APP/PSen transgenic mice had at least one electrographic seizure (Fig. 7b) . The majority included an initiating spike and a 20-60 s run of high amplitude epileptiform activity, and were followed by a post-ictal attenuation of cerebral rhythyms (Fig.  7a) . At the video level, each of the electrographic seizures was accompanied by tonic posturing and myoclonus (Supplementary Movies 3  and 4) . The ictal period commonly includes locomotor hyperactivity and the postictal period is marked by hypoactivity. None of the 12 APP/ PSen transgenic lacking PrP C exhibited an electrographic or behavioral seizure during the 72-h period (Fig. 7b) . Neither the wild-type nor Prnp -/-mice had electrographic abnormalities during similar monitoring, although single spikes were occasionally observed in all genotypes. Thus, the electrographic phenotype of this Alzheimer's disease model requires PrP C .
The seizure phenotype may account for the reduced survival of APP/ PSen mice via status epilepticus, or sudden unexpected death in epilepsy. In the cohort studied here, reduced survival for the APP/PSen genotype was fully rescued by PrP C loss (Fig. 7c) , as in our previous separate analysis 13 . De facto, mice monitored by EEG were selected from the two-thirds of the transgenic mice that escaped early death. Considering both phenotypes together, 70% of the APP/PSen mice suffered either early death or seizures, whereas <4% of the APP/PSen Prnp -/-mice showed one of these phenotypes.
DISCUSSION
Our results describe a Fyn signaling pathway activated by Abo-PrP C complexes. Pathophysiological relevance is supported by the binding of human Alzheimer's disease-derived Abo to PrP C , enrichment of PrP C in PSDs, PrP C dependence of Fyn activation by Abo in neurons, and a requirement for both Fyn and PrP C for Abo-induced changes in NR2B. Short-term activation of this pathway resulted in increases in surface NMDAR and excitotoxicity, followed by dendritic spine npg transgenic mice. The PrP C dependence of both epileptiform activity and early death provides indirect support for this hypothesis.
Although seizure incidence has been reported to increase in Alzheimer's disease, sudden death early in the disease is not typical. The relevance of EEG abnormalities to cognitive dysfunction in Alzheimer's disease requires clinical correlation.
Conclusions
Previous work has shown that Abo bind to PrP C (refs. 5-10) , and, in a number of scenarios, PrP C is essential for the deleterious actions of Abo 5, 10, [13] [14] [15] [16] [17] [18] [19] [20] . We found that Fyn kinase signaling links an Abo-PrP C complex in PSDs to changes in GluR function and dendritic spine anatomy. Notably, Abo from the brains of individuals with Alzheimer's disease interacts with PrP C , and this complex may be involved in human Alzheimer's disease pathogenesis. Furthermore, Fyn provides a molecular link to Tau pathology and to epileptiform phenotypes. Future studies should examine the Abo-PrP C -Fyn pathway in multiple models of Alzheimer's disease to validate its relevance for pathophysiology in different disease stages and manifestations.
METHODS
Methods and any associated references are available in the online version of the paper.
Fyn activation by PrP C Although PrP C and Fyn were associated physically and Ab engagement of PrP C led to Fyn activation, the two proteins are present on different faces of the plasma membrane. PrP C is present on the extracellular side of the membrane, whereas Fyn is present on the intracellular side, and the two polypeptides therefore cannot be in direct physical contact. Lipid rafts are crucial for signal transduction, and cell-bound Abo is known to localize to rafts in a Fyn-dependent manner 26 . It is possible that the coalescence of Abo-PrP C and Fyn in lipid rafts allows signaling without a transmembrane polypeptide partner. However, it seems more plausible that one or more membrane-spanning partners link the two proteins.
Previous reports have described PrP C -dependent signaling in certain cells after antibody cross-linking 17, 24, 25 . We found that clustering of PrP C with antibody to PrP C was not sufficient to induce Fyn activation, as observed with Abo in primary neurons. This suggests that PrP C conformational changes occur when Abo binds to it. The Abo binding domain of PrP C (amino acids 23-111) is thought to be natively disordered, and Abo may stabilize a specific conformation of the protein, leading to signal transduction through Fyn.
Although acute engagement of PrP C by Abo activates Fyn, in vivo levels of Fyn are similar in wild-type and Alzheimer's disease transgenic mice 32 . This is likely related to secondary changes in the chronic state. The biphasic effect of Abo on NMDAR is consistent with compensatory dysregulation. In this regard, it is notable that the STEP phosphatase counteracts Fyn activation and that STEP protein levels are increased in transgenic Alzheimer's disease models and Alzheimer's disease 32, 37 . In culture, early PrP C -dependent Fyn activation was required for the later loss of surface NMDAR, which was correlated with STEP expression. Such compensation may be important in chronic Alzheimer's disease pathophysiology after acute Abo-PrP C -Fyn engagement.
Fyn in PrP C -dependent and Alzheimer's related pathways Our results suggest that Fyn is important for coupling Abo and PrP C to changes in neuronal function. There are multiple lines of evidence linking Fyn kinase function to synapse plasticity and dysfunction in Alzheimer's disease. Fyn is enriched in the PSD and is known to phosphorylate NR2A and NR2B 29 . Mice with loss of Fyn function exhibit reduced LTP, whereas gain of function leads to enhanced LTP and seizures 30, 49 . When Fyn mutants are crossed with APP transgenic mice, Fyn gain of function enhances Alzheimer's disease-related phenotypes, whereas Fyn loss of function ameliorates Alzheimer's disease-related phenotypes 32 . Fyn is known to associate with Tau, and recent data suggest that aberrant Fyn-Tau interactions sensitize synapses to glutamate excitoxicity 50 . PrP C -Fyn signaling may couple Ab and Tau pathologies.
Our data indicate that PrP C and Fyn are essential for certain Aboinduced biochemistry and Alzheimer's disease transgene-dependent phenotypes. Other signaling pathways participating in Ab action include calcineurin, insulin receptors, autophagy, glutamate reuptake and Tau-directed kinases. The interdependence and epistatic relationships between these multiple pathways require further investigation.
Seizures and Alzheimer's disease Mice carrying human Alzheimer's disease transgenes exhibit altered network activity and epileptiform discharges 41 . We confirmed a similar finding in APPswe/PSen1∆E9 mice 42 and found that this phenotype was PrP C dependent and included convulsive seizures. Single spikes without behavioral changes were not a reliable distinguisher between wild-type and APP/PSen transgenic phenotypes in our studies. Given that Fyn gain of function reduces seizure thresholds 49 , Abo-PrP C -Fyn signaling may explain abnormal EEG patterns. It has been suggested that epileptiform discharges explain early death in Alzheimer's disease npg obtained from pre-existing collections, as approved by the Yale Institutional Review Board. Clinical diagnoses were confirmed histologically by examination of adjacent tissue in paraffin sections for abundant Ab plaques and neurofibrillary tangles, Braak stage VI. Demographic and case details are provided in Supplementary Figure 5d . We homogenized 1 g tissue in 5 ml of 25 mM Tris (pH 7.4), 100 mM NaCl and protease inhibitor cocktail (Roche Diagnostics 11836170001) using a polytron. Particulate components were removed after centrifugation at 175,000g for 30 min.
For PrP-Fc affinity resin absorption, TBS-soluble extracts were cleared overnight at 4 °C with Protein A sepharose beads (GE 71-5002-73 AI), followed by 2-h clearance with the same beads cross-linked to human Fc (Jackson Immunoresearch 009-000-008). Equal volumes of cleared extract were incubated 4 h at 4 °C with the same beads covalently cross-linked with either human Fc or recombinant human PrP-Fc. The unbound material was used for activity assays.
Assay of PrP C -interacting Aβ species in brain samples. To prepare capture plates, 20 ml per well of 0 or 100 nM human recombinant PrP(23-111) in 30 mM Na 2 CO 3 and 80 mM NaHCO 3 (pH 9.6) was added to 384-well Black MaxiSorp ELISA plates (Thermo Scientific). After 2 h at 23 ºC, plates were washed with PBS containing 0.05% Tween-20 (PBS-T) and blocked with 5% BSA (wt/vol) in PBS-T (100 ml per well) overnight at 4 ºC. After washing again, samples (50 ml) were applied and incubated for 1 h at 23 ºC. All the samples included added BSA at 0.5%. The plates were then washed and 20 ml per well of rabbit antibody to Ab (#2454, Cell Signaling Technology, 1:1,000 in PBS-T, 0.5% BSA) was added for 1 h. After another wash, plates were incubated with 20 ml per well of biotinylated donkey antibody to rabbit (Jackson Immunoresearch, 1:1000 in PBS-T, 0.5% BSA) for 30 min, washed three times with PBS-T and then incubated with 20 ml of Europium-conjugated streptavidin (1:1,000 in DELFIA Assay Buffer, PerkinElmer). After a final 4× PBS-T wash, 20 ml of DELFIA Enhancement Solution (PerkinElmer) was added to the wells and time-resolved Europium fluorescence was measured using Victor 3V plate reader (PerkinElmer). Background fluorescence values from uncoated wells were subtracted from the corresponding values of PrP C -coated wells.
For PrP(23-111) depletion of Ab from TBS-soluble extracts from the brains of individuals with Alzheimer's disease, samples were incubated in PrP(23-111)-coated wells or uncoated control wells in 96-well BSA-blocked MaxiSorp plates (Nunc 80040LE 0903) for 3 h at 23 ºC. Unbound material was recovered for ELISA. The plates were washed four times with PBS-T, and bound Ab was eluted from PrP(23-111) using 30 ml per well of 10 M urea. The original and recovered extracts, as well as the urea elutions, were assayed for Ab42 using a commercially available kit (Invitrogen KHB3441). Elution fractions were diluted to 1 M urea before ELISA.
Imaging of dendritic spine stability. Hippocampi were dissected from E17-19 mouse embryos and digested with papain (37 ºC, 5% CO 2 for 30 min), and then washed with 1× HBSS. The neurons were transfected with myristoyl-EGFP expression vector using an Amaxa Nucleofector, and plated on poly-d-lysinecoated (100 mg ml -1 ) glass at 100,000 cells per well in 8-well plates (Lab-Tek Chambered Coverslip 155411). Wild-type controls were plated on half of the 8-well dish and either Fyn -/-or Prnp -/-neurons on the other half of the 8-well dish. Culture medium was Neurobasal A supplemented with penicillin/streptomycin, 1 mM sodium pyruvate, 2 mM glutamax and B27 supplement.
Between 19-23 DIV, hippocampal neurons were observed with a 100× objective on a Nikon Eclipse Ti spinning disk confocal microscope using a 488-nm laser. Approximately 25 fixed locations per 8-well dish were imaged on an automated stage every 15 min for 6 h in a 10-mm z stack at 0.1-mm intervals. For the first h, neurons were untreated. After 1 h, neurons were treated with 500 nM
